Share

Save

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

PHASE1NOT_YET_RECRUITING

First in human study to understand the potential side effects of MTX-101, how long MTX-101 lasts in the human body, and how MTX-101 affects specific human immune cells.

info
Simpliy with AI

Study details:

This is a prospective, multi-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MTX-101 in healthy adults (HA) and participants with celiac disease (CeD) and type 1 diabetes (T1D). This study will enroll HAs only in Part A and CeD and T1D patients only in Part B.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Adults, age ≥ 18 and ≤ 65 years at the time of anticipated dosing (Day 1).
  • Healthy individuals without known current or chronic medical conditions, including no history of any autoimmune diseases, in the opinion of the Investigator.
  • Body mass index (BMI) ≥ 18 kg/m2 and ≤ 32 kg/m2.
  • Body weight ≥ 45 and ≤ 100 kg.
  • Negative Coronavirus Disease 2019 (COVID-19) test within 24 hours prior to each dose.
  • Persons of child-bearing potential must have a negative pregnancy test and either abstain from sex or use highly effective method(s) of birth control from Day 1 through the duration of the study.
  • Exclusion criteria

  • Clinically significant findings in physical examination (PE), vital signs (blood pressure, heart rate, and body temperature), electrocardiogram (ECG), and safety laboratory parameters at Screening in the opinion of the Investigator.
  • Renal function calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation with estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m2 or abnormal level of proteinuria detected by dipstick at the time of Screening.
  • Any disease or condition that, in the opinion of the Investigator, might significantly compromise the cardiovascular, hematological, renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) systems.
  • Use of Anti-inflammatory OTC medications, e.g. acetaminophen and ibuprofen, taken within 1 week prior to and during the Screening period.
  • Receipt of an investigational drug within 28 days or 5 half-lives (whichever is longer) of the investigational drug(s) prior to Day 1.
  • Positive serology for human immunodeficiency virus (HIV) type 1 or 2, hepatitis (Hep) B surface antigen, or Hep C.
  • Positive test results for drug screen, including alcohol, at the time of Screening or on Day 1 prior to randomization.
  • Use of tobacco or nicotine-containing products more than the equivalent of 5 cigarettes/week within 30 days prior to (first) dosing.
  • History of receiving a live vaccine within 1 month of Screening.
  • History of splenectomy.
  • History of COVID or influenza vaccine within 2 weeks prior to Screening.
  • Planning to receive any vaccinations during the study period.
  • History of recurrent infections of uncertain cause.
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : Yes

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2024-06-01

    Primary completion: 2025-12-01

    Study completion finish: 2025-12-01

    study type

    Study type

    BASIC_SCIENCE

    phase

    Phase

      PHASE1

    trial

    Trial ID

    NCT06324604

    Intervention or treatment

    DRUG: Placebo

    DRUG: MTX-101

    Conditions

    • Healthy Volunteers
    • Celiac Disease
    • Type 1 Diabetes
    Image related to Healthy Volunteers
    • Condition: Healthy Volunteers, Celiac Disease and more

    • DRUG: Placebo and other drugs

    • Herston, Queensland, Australia

    • Sponsor: Mozart Therapeutics Australia Pty Ltd

    Find a site

    Closest Location:

    Nucleus Network Brisbane

    Research sites nearby

    Select from list below to view details:

    • Nucleus Network Brisbane

      Herston, Queensland, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    PLACEBO_COMPARATOR: Cohort A1S - Healthy Volunteers
    • Cohort A1S (n = 6): MTX-101, Dose level 1 IV or Placebo IV, Single dose
    DRUG: Placebo
    • Placebo
    PLACEBO_COMPARATOR: Cohort A2S - Healthy Volunteers
    • Cohort A2S (n = 6): MTX-101, Dose Level 2 IV or Placebo IV, Single dose
    DRUG: Placebo
    • Placebo
    PLACEBO_COMPARATOR: Cohort A3S - Healthy Vounteers
    • Cohort A3S (n = 6): MTX-101, Dose Level 3 IV or Placebo IV, single dose
    DRUG: Placebo
    • Placebo
    PLACEBO_COMPARATOR: Cohort A4S - Healthy Volunteers
    • Cohort A4S (n =6): MTX-101, Dose Level 4 IV or Placebo IV, single dose
    DRUG: Placebo
    • Placebo
    PLACEBO_COMPARATOR: Cohort A5Sa - Healthy Volunteers
    • Optional Cohort A5Sa (n = 6): MTX-101, Dose level 6 IV or Placebo IV, Single Dose
    DRUG: Placebo
    • Placebo
    PLACEBO_COMPARATOR: Cohort A6M - Healthy Volunteers
    • Cohort A5M (n=8): MTX-101,Dose Level 4 IV or Placebo IV, dosed on Days 1 and 22 for a total of 2 doses
    DRUG: Placebo
    • Placebo
    PLACEBO_COMPARATOR: Cohort A7M - Healthy Volunteers
    • Cohort A6M (n = 6): MTX-101, Dose Level 5 IV or Placebo IV, dosed on Days 1 and 22 for a total of 2 doses
    DRUG: Placebo
    • Placebo
    PLACEBO_COMPARATOR: Cohort A7Ma - Healthy Volunteers
    • Optional Cohort A6Ma (n = 6): Dose Level 6 IV or Placebo IV, dosed on Days 1 and 22 for a total of 2 doses
    DRUG: Placebo
    • Placebo
    PLACEBO_COMPARATOR: Cohort B8 - Celiac Disease or Type 1 Diabetes Patients
    • * Dose Group 1 (n = 6): MTX-101 Dose Level 4 IV Day 1, placebo IV Day 22
    • * Dose Group 2 (n = 6): Placebo IV Day 1, MTX-101 Dose Level 3 IV Day 22
    DRUG: Placebo
    • Placebo
    PLACEBO_COMPARATOR: Cohort B9 -Celiac Disease or Type 1 Diabetes Patients
    • Dose Group 1 (n = 6): MTX-101 Dose Level 5 IV Day 1, placebo IV Day 22 Dose Group 2 (n = 6): Placebo IV Day 1, MTX-101 Dose Level 5 IV (or the maximum tolerated dose in Part A MAD) Day 22
    DRUG: Placebo
    • Placebo
    PLACEBO_COMPARATOR: Cohort A5Sa -Healthy Volunteers
    • Optional Cohort A5Sa (n = 6): MTX-101, up to Dose Level 6 IV or Placebo IV, Single Dose
    DRUG: Placebo
    • Placebo

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Safety of single, ascending dose levels of MTX-101Assess the safety of single, ascending dose levels of MTX-101 by evaluating the incidence, severity, and seriousness of treatment-emergent adverse eventsEnrollment to 8 weeks post dose
    Safety of multiple, ascending dose levels of MTX-101Assess the safety of multiple, ascending dose levels of MTX-101by evaluating the incidence, severity, and seriousness of treatment-emergent adverse eventsEnrollment to 11 weeks following the last dose

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    pharmacokinetics (PK) of MTX-101Characterize the pharmacokinetics (PK) of MTX-101 by measuring the maximum time of occurrence for maximum plasma drug concentration (Cmax)Enrollment to 11 weeks following the last dose
    pharmacokinetics (PK) of MTX-101Characterize the pharmacokinetics (PK) of MTX-101 by measuring the time of occurrence for maximum plasma drug concentration (Tmax).Enrollment to 11 weeks following the last dose
    pharmacokinetics (PK) of MTX-101Characterize the pharmacokinetics (PK) of MTX-101 by measuring the maximum plasma drug concentration (Cmax), minimum plasma drug concentration (Cmin), and area under the plasma drug concentration versus time curve from time 0 to last measurable concentration (AUC(0-t))Enrollment to 11 weeks following the last dose
    anti-drug antibody (ADA) formationEvaluate incidence of anti-drug antibody (ADA) formation by measuring the detect the presence of anti-MTX-101 antibodies in participant's blood.Enrollment to 11 weeks following the last dose

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

    Other trails to consider

    Top searched conditions